IFRX · InflaRx N.V.
$2.08
+0.06 (+2.97%)
At close · Aug 21
Market Cap
$311.68M
Shares
147.37M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$2.02
Open$2.12
Day$2.01–2.15
52W close$0.83–2.74
Avg vol 30d933K
Short int9.3M · 6.3% float · 10.9d
Short vol85%
DataJan 2020–Aug 2026
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 16 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+39%
above
Price vs 50-day avg
+6%
above
RSI (14)
55
neutral
MACD trend
Positive
52-week position
62%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+17%
trailing
6-month return
+120%
trailing
YTD return
+100%
this year
Relative strength
+108%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $2 › 200d $1 — 50d above 200d
Institutional flow
Accumulating
+72% holders QoQ · +29 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
6.33% of float · ▲ +5.0% MoM · 10.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
62 holders — near 3-yr high, broad support
Squeeze score
75
high risk · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
108%
annualized · 1-yr
Max drawdown
−53%
past year
ATR
6.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+39%
Bullish
Price vs 50-day avg
+6%
Bullish
RSI (14)
55
Neutral
MACD trend
Positive
Bullish
52-week position
62%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $2 › 200d $1 — 50d above 200d
Institutional flow
Accumulating
+72% holders QoQ · +29 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
6.33% of float · ▲ +5.0% MoM · 10.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
62 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $1
Now $2 · 62%
Range high $3
vs 200-day avg +39%
vs 50-day avg +6%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
IFRX
this stock
InflaRx N.V.
|
$311.68M | +100.0% | — | — | 6.3% |
|
ONC
BeOne Medicines Ltd.
|
$557.05B | +21.5% | +22179.2% | 856.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$136.93B | +19.2% | +46.2% | 31.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$86.39B | +7.1% | +20.8% | 20.8 | 3.3% |
|
MRNA
Moderna, Inc.
|
$69.62B | +352.1% | +4.3% | — | 12.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| IFRX | +0.5% | +16.8% | +119.6% | +18.8% | +100.0% |
| SPY | -2.0% | +3.3% | +11.2% | +2.1% | +11.8% |
| vs SPY | +2.5% | +13.5% | +108.4% | +16.7% | +88.2% |
Key facts
CIK
1708688
CUSIP
N44821101
13F (30d)
66 filings
62 filers
Visit website
Investor relations